Origin company
Vanquish Bio
The organization behind a network of oncology and clinical-intelligence ventures. Started through Halo Ventures, it inspired Vanquish Cancer and Vanquish Biologics.
vanqbio.comVentures
Our ventures
Companies started or supported through Halo Ventures' consulting and venture-studio work, built with the same playbook we use for clients.
Halo Ventures founder Bryan Allinson also leads or co-leads each company shown here. Each company owns its own name, products and brand.
Companies
Clinical AI for endoscopy and oncology
Vanquish Cancer
Develops PANDA, the Pan Cancer Dx Assistant, for the endoscopic ultrasound encounter: PANDA Discovery before the procedure, PANDA Detect during it, and PANDA Diagnose after it. Lead focus is earlier detection of pancreatic cancer.
Investigational. Not cleared or approved by the FDA.
vanqai.comCell-free biologic therapeutics
Vanquish Biologics
Develops NKEVs, extracellular vesicles from non-tumorigenic human natural killer cells, shipped as a powder for reconstitution at standard infusion centers. Lead indication is advanced pancreatic cancer. Based at Station 41 on the Southern Research campus in Birmingham, with support from Innovate Alabama.
Preclinical. NKEV has not been studied in humans.
vanquishbiologics.comNeedle-free vaccines against Staphylococcus aureus
Pentamer Bio
Needle-free vaccines built on a patented CTA2/B platform, with Boise State University as partner institution. BoStaph™ for dairy cattle is in development under USDA NIFA STTR Phase I and Phase II awards, with planned USDA CVB licensure; human candidates are a microneedle patch and a nasal spray.
BoStaph™ is investigational and not USDA licensed. Human candidates are preclinical and have not been evaluated by the FDA.
pentamerbio.comScope and scale
The work behind the companies
2019Halo Ventures founded
$4M+in grants won across the portfolio
$60Mraised for the UT Horizon Fund, in a prior role
4companies started or supported, in Florida and Alabama, plus client engagements
Grants won
| Company | Source | Amount |
|---|---|---|
| Vanquish Bio | State award | $1.99M |
| Vanquish Bio | Federal award | $400K |
| Vanquish Biologics | Non-profit award | $700K |
| Vanquish Biologics | State award | $100K |
| Pentamer Bio | Federal award | $650K |
| Pentamer Bio | Federal award | $180K |
| Total grants | $4.02M | |
Investment
| Organization | Source | Amount |
|---|---|---|
| Portfolio companies | Angel investment | Confidential |
| UT Horizon Fund (University of Texas System) | Capital raised | $60M |
Funding and grants
- State, federal and non-profit awards
- Multiple NIH SBIR/STTR applications prepared in 2026, with letters, biosketches and budgets
- Post-award budget, compliance and reporting for federal and state awards
Regulatory
- FDA regulatory assessment and pathway strategy for AI software as a medical device
- Pre-submission and Breakthrough Device planning
- IND planning for a cell-derived biologic; USDA CVB planning for an animal vaccine
Clinical and research partnerships
- Research and data agreements with US health systems and universities
- Confidentiality and co-development discussions with academic medical centers
- Licensing from US research universities
Client engagement: Quest, Inc.
- SideLyer, a patented motorized patient-repositioning device developed at Quest, Inc., a nonprofit in Orlando, Florida
- Medical device registration
- Sales and marketing
Market and investors
- International outreach, including MEDICA 2026 in Düsseldorf
- Investor materials and angel-network outreach
- Corporate partner outreach to imaging and endoscopy manufacturers
Let's achieve your business goals, together.
Tell us where you are and where you need to get to. We will reply with how we would approach it.
Contact us today